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Abstract
Background: Strategies to control HIV for improving the quality of patient lives have been aided by the Highly
Active Anti-Retroviral Therapy (HAART), which consists of a cocktail of inhibitors targeting key viral enzymes.
Numerous new drugs have been developed over the past few decades but viral resistances to these drugs in the
targeted viral enzymes are increasingly reported. Nonetheless the acquired mutations often reduce viral fitness and
infectivity. Viral compensatory secondary-line mutations mitigate this loss of fitness, equipping the virus with a
broad spectrum of resistance against these drugs. While structural understanding of the viral protease and its drug
resistance mutations have been well established, the interconnectivity and development of structural cross-
resistance remain unclear. This paper reports the structural analyses of recent clinical mutations on the drug cross-
resistance effects from various protease and protease inhibitors (PIs) complexes.
Methods: Using the 2015 updated clinical HIV protease mutations, we constructed a structure-based correlation
network and a minimum-spanning tree (MST) based on the following features: (i) topology of the PI-binding
pocket, (ii) allosteric effects of the mutations, and (iii) protease structural stability.
Results and conclusion: Analyis of the network and the MST of dominant mutations conferring resistance to the
seven PIs (Atazanavir-ATV, Darunavir-DRV, Indinavir-IDV, Lopinavir-LPV, Nelfinavir-NFV, Saquinavir-SQV, and Tipranavir-
TPV) showed that cross-resistance can develop easily across NFV, SQV, LPV, IDV, and DRV, but not for ATV or TPV.
Through estimation of the changes in vibrational entropies caused by each reported mutation, some secondary
mutations were found to destabilize protease structure. Our findings provide an insight into the mechanism of PI
cross-resistance and may also be useful in guiding the selection of PI in clinical treatment to delay the onset of
cross drug resistance.
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Background
Ever since the identification of the Human Immunodefi-
ciency Virus (HIV) as the cause of Acquired Immuno-
deficiency Syndrome (AIDS), scientists have raced to
find effective and sustainable treatment methods to in-
hibit viral replication and assembly. In the last 30 years
alone, HIV has grown to be a pandemic with more than
35 million people infected worldwide [1]. While thera-
peutic progress has been made in prolonging the lifespan
of infected individuals using the Highly Active Anti-
Retroviral Therapy (HAART) [2–4], HIV rapidly adapts
and develops drug resistance.
Although new drugs such as Protease Inhibitors (PIs)
are constantly being developed, such progress is outpaced
by HIV drug resistance. This drug resistance arises from
mutations in the viral protease gene to compromise the
protease-PI interaction to facilitate the binding to protease
substrate (i.e. Gag), even in the presence of the PIs [5–11];
consequently rendering the PIs ineffective.
While drug resistant mutations are often associated to
specific PIs, many confer cross-resistance to other PIs
[12]. The cross-resistance makes it challenging to map
specific protease mutations to specific PIs. Nevertheless,
to effectively guide clinical selection of second or third
line of treatment when resistance to one such PI has oc-
curred, such investigations are necessary [13]. Mutation
mappings have revealed that these mutations spontan-
eously arise as part of the natural variance [14] and be-
come dominant during PI-drug treatments.
This high variance in the HIV enzymes often results in re-
duced viral fitness (in terms of replication and infectivity) and
an increasing percentage of inactivated or “unfit” viruses [15].
Nonetheless, of the PI-resistance mutations [16], many also
compensate for the reduced viral fitness [17–20]. Such com-
pensatory mutations are typically found outside the protease
active site or on the protease substrate Gag [21–26] to bal-
ance fitness with the impaired enzymatic activity. Through
better surveillance, the reports of such emerging mutations
would certainly enable in-depth investigations into the struc-
tural mechanisms of drug resistance [27, 28].
Current studies of protease structures bearing different
resistance mutations [7, 18–20, 27–33] are generally fo-
cussed on the protease flaps located above the protease
active site and how the flaps mediate PI accessibility.
Mutations in this area naturally affect the flap motions, re-
ducing PI accessibility and binding. While such mutations
can be single point mutations or a cluster to confer resis-
tances to specific PIs, the exact structural mechanisms
that result in cross-drug resistance remain enigmatic.
Using network analyses, Ragland et al. [27] and Appadurai
et al. [28] investigated the relationship of mutations inside
and outside the protease active site. Their studies revealed
allosteric effects that explained resistance development
against the current PIs. While their studies conveyed
residue-based correlations within a protease structure and
for specific PI resistance, the cross-resistance conferred by
different combinations of mutations remains not well
established.
In this study, we investigated different combinations of
protease mutations and how they lead to resistance to
various PIs by constructing a structure-based correlation
network of 33 protease-PI mutant complexes from the
2015-updated clinical drug-resistant mutations in HIV-1
protease [34]. To construct this network, we employed
different structural constraints such as PI-binding pockets
corresponding to various PIs, allosteric effects on the PI-
binding region, and structural stability affected by muta-
tions. In addition, we investigated the mutation hotspots
that can destabilize the protease structure. Together, these
findings can lead to better understanding of PI cross-
resistance and serve as a possible guide in the clinical se-
lection of PIs to delay the onset of PI resistance.
Methods
Structural modelling of mutated complexes of protease
and protease inhibitors (PIs)
We modelled 26 mutated protease structures based on the
various combinations of mutations reported in the 2015 up-
date of drug-resistance mutations in HIV-1 [34]. According
to this report, the mutations were categorized into “major”
(substantially reducing protease binding ability to the PIs)
and “minor” (some compensate and improve the viral fitness
loss caused by major mutations, whereas others affect PI
susceptibility) [34]. These protease mutants are known to be
resistant to the seven Protease Inhibitors (PIs): Atazanavir
(ATV), Darunavir (DRV), Indinavir (IDV), Lopinavir (LPV),
Nefinavir (NFV), Saquinavir (SQV), and Tipranavir (TPV).
As starting points for computational mutagenesis, seven
structures of protease-PI complexes from the Protein Data
Bank (PDB) for the corresponding PIs were selected: ATV
[PDB:3OXX], DRV [PDB:4LL3], IDV [PDB:2B7Z], LPV
[PDB:2Q5K], NFV [PDB:1OHR], SQV [PDB:3S56], and
TPV [PDB:3SPK]. For each protease-PI complex, we used
SCWRL4 [35] to model the side chains of the mutated
residues in the protease. The PI coordinates were then
input into the modelled protease and minimized using
AMBER12 [36].
Constructing the correlation network of the modelled
protease-PI complexes
We simulated the co-related drug resistant mutations
against various PIs by constructing a weighted graph gen-
erated by Gephi v0.82 [37]. The graph G= (V, E) contains a
set of nodes V, each of which represents a protease-PI
complex containing the combinations of major and/or
minor protease mutations [34]. Nodes are connected by
edges E represented by the pairwise structural co-
relationships between nodes.
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To investigate the influence among the nodes, we
assigned node weights using closeness centrality, which
quantifies the closeness of a node to the other nodes in
the network. The nodes with high closeness centrality
show the potentially related mutations that would be se-
lected in resistance development against various PIs.
For each node v in graph G, we characterized a vector Cv
involving (i) PI-binding pocket corresponding to various
PIs and mutations, (ii) allosteric effects on the PI-binding
region caused by the mutations, and (iii) structural stability
affected by the mutations.
(i) PI-binding pocket
The protein cavity detection package fpocket [38] was
used to estimate the PI-binding pocket volume
(Vpocket) for each protease-PI variant and the influence
of the different mutation categories (i.e. major or
minor) on the PI-binding region.
(ii)Allosteric effect
SPACER [39] was used to detect communications and
the impact on the PI-binding regions resulting from
the major and minor mutations. The communication
strengths between sites, characterized by leverage
coupling (details in [40]), imply the potential allosteric
effect (AllosComm defined in our Cv vector) caused by
the various mutations.
Due to the different combinations of mutations,
where some minor mutations do affect the major
mutations and PI susceptibility, we estimated the
AllosComm as below:
1. If the protease-PI complex contains major
mutations do
2. AllosComm← effect of both (major, minor) to
the PI-binding region, excluding effect of minor
onto the major mutations
3. Else:




Thermostability of a native protease [PDB:1ODW]
given the various mutations was evaluated using
ENCoM server [41] and the resulting free energy
(ΔΔG) was assigned to the mutated protease structure
by linearly combining all energy values (including
vibrational entropy and approximated enthalpy
scores) that resulted from each single mutation.
The structural deviations (RMSd) of the resulting
mutated protease from the native protease above
were also calculated.
Therefore in our graph G, we defined an integrated
vector Cv for each node v as
Cv = (Vpocket, AllosComm, ΔΔG, RMSd), and the
weight of the edge between nodes i,j was estimated
based on Pearson’s correlation between two
normalized vectors Cvi and Cvj.
Constructing the minimum spanning tree
After constructing the graph G, a shortest path subgraph H
was extracted by employing the Kruskal’s minimum span-
ning tree (MST) algorithm [42] in Scipy package [43]. In
this subgraph H, nodes were weighted using numbers of
neighbours, and the edges were defined the same as in G.
Results and discussion
Structural relationship of PI-resistance protease mutants
We set out to study the cross-drug resistance of protease
mutations associated with various PIs structurally. To do
this, we estimated the protease pocket volumes of 33
protease-PI complexes using fpocket [38] and calculated
the pocket volume for another seven native protease-PI
complexes [referenced from PDB:1ODW]. Results of the
seven native complexes showed that the protease pocket
volume was capable of flexible adjustment in accordance
to the PI size (Tables 1, 2, 3 and 4) and that even a sin-
gle mutation can alter the pocket volume of HIV prote-
ase (see Additional file 1).
In the three wild type protease-PI complexes: DRV_0,
LPV_0, and NFV_0, naturally occurring single residue
substitutions S37N, L63P, and V3I, respectively, were
found to shrink the PI-binding pocket (~30% decrease in
DRV_0 and LPV_0, and ~10% decrease in NFV_0). This
may explain the strong binding of wild-type proteases
with the PIs (with low dissociation constant Kd = 0.0027
nM [10], inhibitor dissociation constant Ki = 0.005 nM
[44], and Ki = 0.53 - 2 nM [45] respectively).
When major mutations (e.g. at positions 46, 50, 54, 84,
and 90) were introduced, as shown for ATV_0, IDV_0,
IDV_1, LPV_1, and NFV_1 (Tables 1, 2 and 3), the bind-
ing pocket volume increased. This agrees with the in vitro
findings that combinations of these mutations known as
“quadruple mutant” caused multi-drug resistance [46].
To further investigate the mechanism, we analyzed the ef-
fects of these mutations on the PI-binding site using SPA-
CER [39]. We found that both the major and minor
mutations influenced the PI-binding pockets. The quadruple
mutant-containing complexes (ATV_0, IDV_0, LPV_1, and
NFV_1) showed increased allosteric effects when compared
to the native complexes (Tables 1, 2 and 3). In addition,
some minor mutations at position 82, demonstrated a
strong effect on the binding region (in NFV_3, NFV_4,
SQV_3, or SQV_4 complexes) when mutated to hydrophilic
residues.
To investigate the structural stability of the mutated
proteases, we first checked for possible biases in side chain
replacement by SCWRL4 [35]. As a control, the replace-
ment protocol was applied on the native protease [PDB:
1ODW], where all the side chains were first removed and
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added back to the retained backbone. Our results of
superimposed full structures of the original native and the
reconstituted structures showed that SCWL4 was able to
recover the side chains of the native structure (RMSd ~
0 Å). Thereafter, SCWRL4 was used to model the mutated
side chains for all the protease mutants. ENCoM [41] was
used to estimate the free energy and vibrational entropy
and we found that the mutations destabilized the protease
structure even though they caused reductions of PI sus-
ceptibility (Tables 1, 2, 3 and 4). In addition, it was shown
that mutations might have caused structural changes in
some mutated protease structures when compared to the
native protease (i.e. RMSd values in Tables 1, 2, 3 and 4).
Yet these values are unlikely to reflect the structural effect
caused by single mutations. Nonetheless, we have incor-
porated the RMSd factor into our integrated vector Cv to
construct the correlation network. This was performed to
include the structural contribution effect in the network,
and also to avoid the possible biases toward allosteric
communication and free energy.
Using the multiple structural constraints shown in
Tables 1, 2, 3 and 4, we generated a structure-based
Table 1 Structural characterized features used in the graph constructions for the PI-resistance mutants to ATV and DRV
Vpocketa (Å3) AllosCommb ΔΔG score / ΔSc (kcal/mol) RMSd (Å)
Atazanavir (ATV) — molecular weight = ~705 g/mol
ATV_0 (major/minor) 2484.44 (2325.65) 0.721 (0.402) 1.13 / −0.13 0.93
ATV_1 (major/minor) 1675.04 0.848 (0.761) 8.74 / −3.20 1.11
ATV_2 (minor) 1779.57 0.206 (0.668) 5.21 / −1.75 1.07
ATV_3 (minor) 2009.24 0.268 (0.81) 1.94 / −1.93 1.05
ATV_4 (minor) 1895.13 0.206 (0.756) 1.50 / 0.02 1.06
ATV_5 (minor) 1884.48 0.014 (0.879) 0.30 / −0.009 1.01
Darunavir (DRV) — molecular weight = ~548 g/mol
DRV_0 (wt) 1310.9 (1842.30) 0.692 (0.269) −1.31 / −0.59 0.83
DRV_1 (major/minor) 1570.52 0.667 (0.635) 3.54 / 1.91 1.09
DRV_2 (major) 1636.82 0.521 (0.765) −0.13 / −0.06 1.07
aPocket volume of the native protease [PDB: 1ODW], which contains no mutations in the presence of corresponding PIs, is shown in parentheses for comparison
purpose. In the cases of wild type proteases DRV_0, there is a single mutation found (i.e. S37N) in the structures when compared to the native protease sequence.
The complexes that contain the quadruple mutants and show increased pocket volume are in bold
bFor comparison purposes of allosteric effect, communication estimated values of the native protease were shown in parentheses
cΔΔG and ΔS scores represent free energy and vibrational energy respectively, demonstrating thermo-stability of the protease when mutated from the
native protease
Table 2 Structural characterized features used in the graph constructions for the PI-resistance mutants to IDV and LPV
Vpocketa (Å3) AllosCommb ΔΔG score / ΔSc (kcal/mol) RMSd (Å)
Indinavir (IDV) — molecular weight = ~614 g/mol
IDV_0 (major/minor) 1929.67 (1863.57) 0.989 (0.745) −1.37 / −1.18 1.14
IDV_1 (major/minor) 1884.57 0.770 (0.825) 4.32 / −0.45 1.09
IDV_2 (major/minor) 1769.62 0.518 (0.468) 2.14 / 0.72 1.04
Lopinavir (LPV) — molecular weight = ~629 g/mol
LPV_0 (wt) 1659.68 (2201.32) 0.696 (0.257) 0.13 / 0.34 0.88
LPV_1 (major/minor) 1872.66 0.590 (0.547) 4.53 / 0.58 1.0
LPV_2 (major/minor) 1867.24 0.665 (0.452) 1.51 / −0.15 0.98
LPV_3 (major/minor) 1781.42 0.8 (0.646) 4.28 / 1.47 1.06
LPV_4 (major/minor) 2029.70 0.769 (0.646) 1.51 / 0.48 1.08
LPV_5 (minor) 2051.45 0.167 (0.944) 1.28 / 0.62 1.08
LPV_6 (minor) 2034.89 0.385 (0.944) 2.27 / 0.78 1.08
aPocket volume of the native protease [PDB: 1ODW], which contains no mutations in the presence of corresponding PIs, is shown in parentheses for comparison
purpose. In the cases of wild type proteases LPV_0, there is a single mutation found (i.e. L63P) in the structures when compared to the native protease sequence.
The complexes that contain the quadruple mutants and show increased pocket volume are in bold
bFor comparison purposes of allosteric effect, communication estimated values of the native protease were shown in parentheses
cΔΔG and ΔS scores represent free energy and vibrational energy respectively, demonstrating thermo-stability of the protease when mutated from the
native protease
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correlation network of the mutant protease-PI complexes
with respect to various PIs (Fig. 1). Figure 1 shows that mu-
tations associated with the seven PIs are highly related
where cross-resistance could develop easily against NFV,
SQV, LPV, IDV, or DRV (Fig. 1b), with the arrows indicating
the predominant directions of the correlations. The results
suggest that LPV should be used as the first line of treat-
ment to reduce the development of cross-resistance (since
the arrows point from the other drugs to LPV and not vice
versa, see Fig. 1b).
We next constructed a MST to extract the shortest
path between the different PI resistant proteases from a
wild type protease (i.e. complex of protease-DRV at the
bottom of the MST). Our MST demonstrates a path
(Fig. 2) for a wild type protease to develop resistance
from one PI to another, serving as a guide for the struc-
tural relationships among different protease mutants to
various PIs.
The MST was sectioned into four main groups: (I), (II),
(III), and (IV) as shown in Fig. 2. The major group III (in-
cluding most of major mutations-containing protease-PI
complexes, i.e. DRV_1, IDV_1, ATV_1, TPV_1, LPV_1, and
SQV_1) was connected to the other groups at ATV_2 (to
group II) and at SQV_1 (to group IV). The other major re-
sistant mutant NFV_1 however belonged to group I. As the
connections between the mutant complexes were weighted
based on their structural correlations (see Methods), the
thicker edges demonstrated the high likelihood of cross-
resistance to the next PI in the tree.
In the major group III, strong connections between pro-
tease mutants that resist DRV (i.e. DRV_1) and IDV (i.e.
IDV_1) were observed. This connection was supported by
clinical findings where the combinations of mutations
V32I, I47A, and L76V, conferred high-level resistance to
DRV and IDV [34]. The path thus further dissuades the
use of DRV on patients with IDV resistant viruses.
Table 3 Structural characterized features used in the graph constructions for the PI-resistance mutants to NFV and SQV
Vpocketa (Å3) AllosCommb ΔΔG score / ΔSc (kcal/mol) RMSd (Å)
Nelfinavir (NFV) — molecular weight = ~568 g/mol
NFV_0 (wt) 1637.23 (1823.01) 0.584 (0.101) −1.23 / −0.58 0.6
NFV_1 (major/minor) 1841.98 0.655 (0.403) 2.08 / −0.70 1.09
NFV_2 (minor) 1634.29 0.308 (0.312) 0.62 / −0.63 1.03
NFV_3 (minor) 1669.08 0.795 (0.713) 0.51 / 0.28 0.98
NFV_4 (minor) 1692.91 0.851 (0.713) 0.68 / 0.21 0.98
Saquinavir (SQV) — molecular weight = ~671 g/mol
SQV_0 (minor) 1735.73 (2193.99) 0.735 (0.38) 3.27 / 1.46 0.84
SQV_1 (major/minor) 1700.44 0.787 (0.371) 6.02 / −1.89 0.81
SQV_2 (minor) 1631.92 0.601 (0.346) 0.22 / −0.61 0.82
SQV_3 (minor) 1817.81 0.739 (0.441) 2.14 / 0.72 0.79
SQV_4 (minor) 1531.07 0.748 (0.606) 0.67 / 0.21 0.8
aPocket volume of the native protease [PDB: 1ODW], which contains no mutations in the presence of corresponding PIs, is shown in parentheses for comparison
purpose. In the cases of wild type proteases NFV_0, there is a single mutation found (i.e. V3I) in the structures when compared to the native protease sequence.
The complexes that contain the quadruple mutants and show increased pocket volume are in bold
bFor comparison purposes of allosteric effect, communication estimated values of the native protease were shown in parentheses
cΔΔG and ΔS scores represent free energy and vibrational energy respectively, demonstrating thermo-stability of the protease when mutated from the
native protease
Table 4 Structural characterized features used in the graph constructions for the PI-resistance mutants to TPV
Vpocketa (Å3) AllosCommb ΔΔG score / ΔSc (kcal/mol) RMSd (Å)
Tipranavir (TPV) — molecular weight = ~603 g/mol
TPV_0 (major/minor) 1912.49 (1963.76) 0.627 (0.277) 3.54 / 0.42 0.97
TPV_1 (major/minor) 1858.07 0.741 (0.795) 8.99 / 3.12 1.03
TPV_2 (major/minor) 1804.05 0.905 (0.287) 0.90 / 0.7 1.05
TPV_3 (minor) 2228.93 0.24 (0.379) 4.43 / 1.3 1.02
aPocket volume of the native protease [PDB: 1ODW], which contains no mutations in the presence of corresponding PIs, is shown in parentheses for
comparison purpose
bFor comparison purposes of allosteric effect, communication estimated values of the native protease were shown in parentheses
cΔΔG and ΔS scores represent free energy and vibrational energy respectively, demonstrating thermo-stability of the protease when mutated from the
native protease
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Interestingly, the MST distinguished NFV_1 from the
other major mutants. A distinct mutation D30N around
the NFV-binding region might characterize the specifi-
city of the NFV_1 complex (Fig. 2 and Table 3). How-
ever, this D30N mutation is rarely associated with NFV-
resistance in some non-subtype B HIV [34], suggesting
that NFV can be used as a first-line therapy to avoid the
rapid development of resistance to other PIs.
Our structural and sequence analyses showed that mu-
tations at the protease flap regions (position 46–54) and
residue 90 (i.e. L90M) played a key role to distinguish
group III from the other groups. In the major resistance
protease mutants (i.e. group III), the flap region mutations
were predominantly hydrophobic and accompanied by
mutations at position 90 (e.g. L90M), whereas in the other
minor resistance protease mutants, the flap regions were
mostly hydrophilic with no mutations occurring at pos-
ition 90 (Fig. 2). The physicochemical changes of the flap
regions may have caused rigid or buried flaps, resulting in
reduced PI susceptibility.
However, an exception to this trend was found for
I50L in the mutant ATV_1 previously reported to im-
prove susceptibility to IDV, SQV, LPV, or NFV [47–49].
In our MST, we further defined this relationship where
ATV_1 was closer to IDV_1, SQV_1, and LPV_1 than to
NFV_1, suggesting that NFV_1 resistance would develop
Fig. 1 Structure-based correlation network of the mutant protease-PI complexes. a Thirty-three protease-PI mutant complexes (represented by nodes)
are coloured according to seven PIs: Atazanavir (ATV, cyan), Darunavir (DRV, blue), Indinavir (IDV, red), Lopinavir (LPV, yellow), Nefinavir (NFV, magenta),
Saquinavir (SQV, green), and Tipranavir (TPV, purple). The protease-PI complexes are numbered following indices: 0 (the PDB available complex structure
that was used to initiate the reported mutations), 1 (mutated protease-PI complexes containing both major and minor mutations), the rest from 2 to 6
(mutated protease-PI complexes containing minor mutations). In this network, edges are coloured based on the source node, which are connected to
other nodes; hence highlighting the link from one node to the others. The node sizes are varied based on different related closeness level of each
node to other nodes. b A consolidated graph that shows predominant trends that the protease is most likely to resist, from one PI to another. The
thicker the arrows are, the more likelihood that protease mutations extend the resistance to the corresponding PIs. The graph was generated using
Gephi v0.82 [37]
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slower when compared to the others. On the other hand,
the other drug resistance mutations (IDV_1, SQV_1,
LPV_1) would develop intervening intermediates
(LPV_3 for IDV_1 and TPV_1 for the latter two).
For group IV, the path depicted that patients first
treated with NFV (i.e. NFV_0 –wild type protease) may
develop significant changes, e.g. in the flap region at pos-
ition 54, and at the hotspot 82 in order to resist SQV. For
patients treated with LPV (i.e. LPV_0 – wild type prote-
ase), there may be a series of resistance developed against
NFV, SQV, and TPV by a single or a few minor mutations
(Fig. 2, group IV). This suggests for the displacement of
SQV instead of NFV in clinical use to avoid rendering
LPV ineffective later.
Detecting protease structure stability-affecting hotspots
Major mutations typically confer PI resistance but also
cause viral loss of fitness. This loss is often in turn com-
pensated by other minor mutations. In our findings, we
showed that the major mutations destabilized protease
structure via increased vibrational entropy (calculated by
ENCoM [41]), and this vibrational entropy contributed
significantly to the free energy of proteins [50]. To
evaluate the reliability of the ENCoM findings, we used
CUPSAT server [51] and found 63% (12/19) agreement
in the calculation of the single mutations.
As shown in Fig. 3, many minor and even major muta-
tions caused protease structure to be unstable in the course
of resistance development. Resistance to DRV, LPV, and
TPV resulted in noticeable stability impact as they contain
the destabilizing major mutations (Tables 1, 2, and 4). With
60% (6/10) mutations causing the instability, viral resistance
to escape from the strong DRV binding [10] comes with
significant structural stability compromise.
Of these mutations, residue substitutions at the flap
regions I47V (in all PI resistance), I50V (in DRV and
LPV), and the mutation L76V (in DRV and LPV) signifi-
cantly increased the regional entropy. While similar
protease-destabilizing effect by major mutations was ob-
served in LPV and TPV resistance, the minor mutation
G73S (LPV) or I54A (TPV) amplified this effect while
compensating for the viral fitness loss.
Conclusion
Based on the structural responses and viral fitness cost
of the clinically reported mutations, we report a PI
resistance-related pathway that HIV protease may
undertake in PI cross-resistance. In this we found the
structural rationale for the rapid development of cross-
resistance amongst five of the seven clinically used PIs.
There are some PIs that would be better used in clinical
settings against naïve HIV infections or when resistance
Fig. 2 The drug resistance-related pathway that Protease might travel to resist from one PI to another. The minimum spanning tree or MST (left)
shows the shortest path that leads to different PI resistance from a wild type protease (e.g. complex of protease-DRV at the bottom of the MST).
Nodes are coloured and scaled the same as shown in Fig. 1 according to seven PIs: Atazanavir (ATV, cyan), Darunavir (DRV, blue), Indinavir (IDV,
red), Lopinavir (LPV, yellow), Nefinavir (NFV, magenta), Saquinavir (SQV, green), and Tipranavir (TPV, purple). Edge thickness is weighted based on
correlation between nodes. Highlighted on the right are the major (in bold) and minor mutations that could distinguish four close groups
of mutant protease complexes (namely group I, II, III, and IV): PI-binding site region (position 30, 32), protease flap region (position 46–54), and other
important major mutations (position 76, 82, 84, and 90). Protease-PI complexes containing major mutations are highlighted in bold. The graph was
generated using Gephi v0.82 [37]
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has already been developed towards another PI. On this,
our findings suggest the use of LPV as the first line of PI
in HAART, and depending on the emergence of PI-
resistant mutations, certain drugs would be more useful in
subsequent lines of treatment. The findings of this study
thus provides a structural understanding that may be use-
ful to guide the clinical use of PIs in HAART, aiding in
drug selection to prolong the effectiveness of the given PI.
Additional file
Additional file 1: Dynamic changes of pocket volumes of three wild type
protease-PI complexes during 10 ns molecular dynamics simulation. The
three wild type protease-PI complexes (DRV_0, LPV_0, and NFV_0) contain
single residue substitutions S37N, L63P, and V3I respectively that contributed
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